Zhejiang Xinlifei Biotechnology

Zhejiang Xinlifei Biotechnology is a clinical-stage biopharmaceutical company focused on developing next-generation cell therapies for solid tumors. Based in Deqing, Zhejiang, the company utilizes its proprietary Super CAR-T platform to overcome the immunosuppressive microenvironment of solid tumors. Their lead program, XL-001, is a GPC3-targeted CAR-T therapy currently in Phase 1 clinical development for hepatocellular carcinoma. The company's technology aims to improve the efficacy, safety, and persistence of CAR-T cells in treating non-hematological cancers. Xinlifei maintains its own GMP manufacturing facilities to support its clinical pipeline and future commercialization efforts.